May 26, 2023 5:36 am | 1 minute read
- Merck & Co Inc MRK announced data from the last pre-determined overall survival (OS) analysis of the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 study evaluating Keytruda (pembrolizumab) plus Eisai Co Ltd ESALY Lenvima (lenvatinib) for initial treatment of advanced renal cell carcinoma (RCC).
- These data will be presented at the upcoming annual meeting of the American Society of Clinical Oncology.
- Also read: Merck and Eisai delay Keytruda-Plus-Lenvima combination study in skin cancer, disappointing in certain types of colorectal cancer.
- After four years of follow-up, Keytruda plus Lenvima maintained a clinically meaningful OS advantage over sunitinib and reduced the risk of death by 21%.
- The estimated OS rates at 24 and 36 months were 80.4% and 66.4% for Keytruda plus Lenvima versus 69.6% and 60.2% for Pfizer Inc PFE Sutent (sunitinib) or
- Keytruda plus Lenvima reduced the risk of disease progression or death by 53%, with a median progression-free survival (PFS) of 23.9 months versus 9.2 months for sunitinib.
- The objective response rate (ORR) was 71.3%, with a complete response rate (CR) of 18.3% for Keytruda plus Lenvima compared to an ORR of 36.7% with a CR rate of 4.8% for sunitinib .
- There were no new safety signals and the safety profile at the final OS analysis was consistent with that of the primary analysis.
- Price promotion: MRK shares closed at $112.30 on Thursday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
